Korro Bio(US:KRRO) ZACKS·2025-11-12 23:41Core Insights - Korro Bio, Inc. reported a quarterly loss of $1.92 per share, which was better than the Zacks Consensus Estimate of a loss of $2.61, representing an earnings surprise of +26.44% [1] - The company generated revenues of $1.09 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 27.33%, compared to zero revenues a year ago [2] - The stock has underperformed the market, losing about 13.8% since the beginning of the year, while the S&P 500 gained 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$2.42 on revenues of $1.5 million, and for the current fiscal year, it is -$10.26 on revenues of $4.84 million [7] - The estimate revisions trend for Korro Bio, Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Korro Bio, Inc. belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Nutriband Inc. (NTRB), is expected to report a quarterly loss of $2.13 per share, with revenues projected at $0.68 million, reflecting a year-over-year increase of 4.6% [9]